<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04750304</url>
  </required_header>
  <id_info>
    <org_study_id>RNI 2020 COUDEYRE</org_study_id>
    <nct_id>NCT04750304</nct_id>
  </id_info>
  <brief_title>Evaluation of the Use of an E-health Therapeutic Education Application for Osteoarthritis Patients</brief_title>
  <acronym>ARTHe 2</acronym>
  <official_title>Evaluation of the Use of an E-health Therapeutic Education Application for Osteoarthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Openium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Caleden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovatherm</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BPIfrance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis is the most common joint disease affecting the joint in a comprehensive and&#xD;
      progressive manner. It leads to increasing disability.&#xD;
&#xD;
      The recommendations of recent years favor the non-pharmacological treatment of osteoarthritis&#xD;
      including regular physical activity, therapeutic education and weight loss Osteoarthritis&#xD;
      population has a low level of physical activity due to a lack of information, motivation and&#xD;
      false beliefs related to physical activity and kinesiophobia (fear of movement) A preliminary&#xD;
      qualitative study (ARTHe1) evaluating the barriers and levers of the use of an e-health&#xD;
      therapeutic education application in patients with osteoarthritis was carried out in order to&#xD;
      guide the development of the ARTHe application.&#xD;
&#xD;
      The objective of this study is to have the application tested on a panel of patients in order&#xD;
      to assess the benefits of using the application in terms of adherence to the practice of&#xD;
      physical activity but also in clinical terms on function and pain, and the satisfaction of&#xD;
      the patient&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational study including the evaluation of the use of the ARTH-e&#xD;
      application after 3 weeks, 6 weeks and 3 months of use.&#xD;
&#xD;
      Patient recruitment will be done in the PRM department of Clermont-Ferrand University&#xD;
      Hospital A subgroup of patients will receive a Garmin VivoSmart 4 connected wristband, which&#xD;
      will record intrinsic stress measurement data during the test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Excercie adherence</measure>
    <time_frame>3 weeks</time_frame>
    <description>Measured with Exercice Adherence Rating Scale (EARS) on 5 point Likert scale, 0= totally agree, 5 = totally disagree</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Excercie adherence</measure>
    <time_frame>6 weeks</time_frame>
    <description>Measured with Exercice Adherence Rating Scale (EARS) on 5 point Likert scale, 0= totally agree, 5 = totally disagree</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Excercie adherence</measure>
    <time_frame>3 months</time_frame>
    <description>Measured with Exercice Adherence Rating Scale (EARS) on 5 point Likert scale, 0= totally agree, 5 = totally disagree</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>3 weeks, 6 weeks, 3 months</time_frame>
    <description>average pain of the 3 prior days, collected on phone interview with analogic visual scale (0 = no pain, 10 = maximum pain )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional evaluation</measure>
    <time_frame>3 weeks, 6 weeks, 3 months</time_frame>
    <description>Collected on the phone with Knee injury and Osteoarthritis Outcome Score (KOOS).&#xD;
This questionnaire contains 17 statements answering the question &quot;During the last eight days, what was your difficulty with each of the following activities?&quot; &quot;. The responses range from &quot;absent&quot; (0 points) to &quot;extreme&quot; (4 points). The maximum score is 68. A high score is predictive of functional degradation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Collection after 3 months of use, of the evaluation of the application via a quality questionnaire in 3 parts including the general user experience, closed questions on the user interface and open questions on user expectations, this questionnaire will be sent by email.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of opening the application per week</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Collection of application usage parameters in a codified manner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of opening the application with on exercice session per week</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Collection of application usage parameters in a codified manner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent on the application at each opening</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Collection of application usage parameters in a codified manner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sessions carried out on a level before moving to the next level</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Collection of application usage parameters in a codified manner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating of exercice session (out of 5 stars)</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Collection of application usage parameters in a codified manner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of positive responses to questionnaires true / false</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Collection of application usage parameters in a codified manner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average weekly pain level</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Average pain level will be asked on the application at most twice a week. Collection of application usage parameters in a codified manner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily number of steps</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Collection of intrinsic activity data for a subgroup using a connected bracelet Garmin in vivo 4, in a codified manner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of movement</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Intensity of movement per day using Metbolic Equivalebt Task (MET) scale will be collected for a subgroup using a connected bracelet Garmin in vivo 4, in a codified manner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily heart rate</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Daily average, minimum and maximum heart rate will be collected for a subgroup using a connected bracelet Garmin in vivo 4, in a codified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily heart variability</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Collection of intrinsic activity data for a subgroup using a connected bracelet Garmin in vivo 4, in a codified manner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily energy expenditure</measure>
    <time_frame>From day 1 to 3 months</time_frame>
    <description>Daily energy expenditure in calories will be collected for a subgroup using a connected bracelet Garmin in vivo 4, in a codified manner</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Application ARTHe</intervention_name>
    <description>Patient will use ARTHe Application for 3 months</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with knee arthritis and using a smartphone&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years&#xD;
&#xD;
          -  Patients with osteoarthritis according to the ACR (American College of Rheumatology)&#xD;
             criteria, symptomatic and diagnosed before inclusion by a specialist or not.&#xD;
&#xD;
          -  Patients with least one knee impairment&#xD;
&#xD;
          -  Patients with a smartphone or tablet with at least Android 5 or iOS 11.&#xD;
&#xD;
          -  Volunteer patients willing to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with no diagnostic criteria for ACR.&#xD;
&#xD;
          -  Patients with comprehension disorders making it impossible to interview and complete&#xD;
             questionnaires or use the application.&#xD;
&#xD;
          -  Refusal to participate or being already included in a research protocol that could&#xD;
             influence the current protocol.&#xD;
&#xD;
          -  Patients under guardianship, curatorship or deprived of liberty.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lise Laclautre</last_name>
    <phone>0473754963</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Aura</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>lise laclautre</last_name>
      <phone>0473754963</phone>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel COUDEYRE, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Gonarthrosis</keyword>
  <keyword>smarthpone application</keyword>
  <keyword>e-Health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

